Skip to main content

By Biocat

The Innovative Medicines Initiative (IMI) has opened its ninth call for proposals with a total budget of €135 millions (€63 millions through the 7th Framework Program and €72 millions from the European Federation of Pharmaceutical Industries) to fund pharmaceutical and biopharmaceutical research projects in the European Union. The budget for the previous call was €242.7 millions.

The scientific topics included in the call are:

  • Paving the way for new treatments to prevent or delay frailty and muscle loss in the elderly (€49.31 millions).
  • Harnessing the power of the Internet and social media to detect reports of adverse reactions to medicines and monitor drug safety (€4.56 millions).
  • Reinvigorating investment in R&D&i and responsible use of antibiotics (€9.4 millions).
  • Clinical development of antibiotics against resistant pathogens (€72.1 millions).

Proposals to the IMI call must be submitted through a consortium of at least two bodies (SMEs, research bodies, universities, patients’ associations or any other non-EFPIA organization). The first step is to submit an Expression of Interest before 9 October 2013, from which a preliminary selection will be made of consortia to submit complete proposals.

More information on the call for proposals and informational sessions is available on the IMI website. In Barcelona, a session was held on 28 June as announced in the upcoming events in the sector section of the Biocat website.

Questions: infodesk@imi.europa.eu

Noteworthy presence of Catalonia

Catalonia is participating in 18 of the 40 projects the IMI currently has underway, through companies (Almirall, Esteve, Synapse Research, Chemotargets and Neuroscience Technologies), bodies (Vall d'Hebron Research Institute, Barcelona Institute for Global Health, August Pi i Sunyer Biomedical Research Institute, IMIM Foundation, Catalan Institute of Cardiovascular Sciences, Catalan Institute of Pharmacology and MAR Health Park) and universities (Pompeu Fabra University, University of Barcelona and Autonomous University of Barcelona).

  • Abirisk (Anti-Biopharmaceutical Immunization
  • Combacte (Combatting Bacterial Resistance in Europe
  • Direct (Diabetes research on patient stratification)
  • EMIF (European Medical Information Framework)
  • Emtrain (European Medicines Research Training Network)
  • eTox (Integrating bioinformatics for the development of Expert systems allowing the in silico prediction of toxicities)
  • Eu2P (European programme in Pharmacovigilance and Pharmacoepidemiology)
  • EUPATI (European Patients' Academy on Therapeutic Innovation)
  • Europain (Understanding chronic pain and improving its treatment)
  • Open PHACTS (The Open Pharmacological Concepts Triple Store)
  • Pharma-Cog (Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development
  • Pharmatrain (Pharmaceutical Medicine Training Programme
  • PRO-active (Physical Activity as a Crucial Patient Reported Outcome in COPD
  • Protect (Pharmacoepidemiological research on outcomes of therapeutics by a European consortium
  • Safe-T (Safer and Faster Evidence-based Translation)
  • SafeSciMET (European Modular Education and Training Programme in Safety Sciences for Medicines)
  • Translocation (Molecular basis of the bacterial cell wall permeability)
  • U-Biopred (Unbiased biomarkers for the prediction of respiratory disease outcomes)
Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.